sudok1 / iStockphoto.com
Drug companies can take heart from a range of best practices in the battle against counterfeit medicines, as LSIPR finds out.
Disease complications, antibiotic resistance, and even death. These are just some of the consequences counterfeit drugs can have.
According to the World Health Organization (WHO), up to two billion people cannot get medicines that are crucial to their health, while many millions are at risk of falling into abject poverty due to healthcare costs they cannot afford. The organization says that this limited access to quality medicines “creates a vacuum that is too often filled by substandard and falsified products”.
The WHO estimates that one in ten medical products circulating in low and middle-income countries is either substandard or counterfeit.
To continue reading this article and to access our full archive, digital magazines and special reports you will need a subscription.
If you have already subscribed please login.
For multi-user price options, or to check if your company has an existing subscription we can add you into, please email Atif at firstname.lastname@example.org
If you have any technical issues please email tech support.
For access to the complete website and archive choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial select ‘TWO WEEK FREE TRIAL’.
counterfeit, bigpharma, generics, counterfeit medicines, patents, World Health Organization, WHO,Alban Kang, Bird & Bird, Rouse, Gunawan Suryomurcito